News | July 29, 2011

FDA Issues Draft Guidance on Device Changes Warranting New Premarket Review


July 29, 2011 — The U.S. Food and Drug Administration (FDA) this week issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.

The 510(k) process is the most common review path to market for lower-risk medical devices. To legally market a device, manufacturers must submit a premarket notification, or 510(k), demonstrating that the new or modified product is substantially equivalent to another legally marketed medical device. 

Manufacturers often make changes or modifications to a device after FDA clearance such as incorporating new technology or upgrading certain aspects of the device. Many changes do not require a 510(k) submission. But when the changes could significantly affect the product’s safety or effectiveness or constitute a major change to the intended use of the device, another 510(k) must be submitted.

“We are making the regulatory process for medical devices less challenging by better describing our expectations,” said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “In particular, manufacturers can continue to make innovative improvements to their devices and better plan for any updated submissions. This saves time and money.”

The draft guidance clarifies the kinds of changes that trigger the need for a new submission, such as specific kinds of labeling changes, changes to the technology used in the device, changes in performance specifications, manufacturing changes, and changes in the materials used in the manufacture of the device. 

This draft guidance is one of 25 action items listed in the FDA’s Plan of Action for Implementation of 510(k) and Science Recommendations launched in 2011 to enhance predictability, consistency, and transparency of the FDA’s premarket review programs. 

For more information: www.fda.gov


Related Content

News | Cardiac Imaging

Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at ...

Home December 19, 2024
Home
News | Cardiac Imaging

Dec. 11, 2024 — Genetesis, Inc. has launched the CardioFlux Membership program. CardioFlux Membership is designed to be ...

Home December 18, 2024
Home
News | Cardiac Imaging

Nov. 13, 2024 – A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing ...

Home November 13, 2024
Home
News | Cardiac Imaging

Oct. 15, 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage ...

Home October 16, 2024
Home
News | Cardiac Imaging

Oct. 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend ...

Home October 15, 2024
Home
News | Cardiac Imaging

PHOTO CAPTION: The Elucid PlaqueIQ user interface is a fully interactive visualization of the patient’s coronary anatomy ...

Home October 01, 2024
Home
News | Cardiac Imaging

Aug. 21, 2024 — NANO-X IMAGING LTD recently announced that its deep-learning medical imaging analytics subsidiary, Nanox ...

Home August 22, 2024
Home
News | Cardiac Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Home July 23, 2024
Home
News | Cardiac Imaging

July 12, 2024 — Researchers have developed a groundbreaking method for analyzing heart MRI scans with the help of ...

Home July 12, 2024
Home
News | Cardiac Imaging

June 10, 2024 — New expert consensus from the Society of Cardiovascular Computed Tomography (SCCT) reviews previously ...

Home June 10, 2024
Home
Subscribe Now